Neurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability

A recent comprehensive study, published in The Lancet Neurology, has revealed staggering figures regarding neurological conditions worldwide. In 2021, over 3 billion individuals were found to be living with such…

Read MoreNeurological Conditions Impact Over 1 in 3 Individuals, Ranking as the Primary Cause of Global Illness and Disability

Ionis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment

Ionis has unveiled encouraging outcomes from its Phase 2 investigation of ION224, a DGAT2 antisense inhibitor aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH), previously termed nonalcoholic steatohepatitis (NASH). The study,…

Read MoreIonis Reports Encouraging Findings from Phase 2 Trial of ION224, Showing Clinical Effectiveness in NASH/MASH Treatment